These characteristic performances significantly improved the accumulation of PUN@Cas‐PT to enhance the gene‐editing efficiency at tumor site as well as attenuated off‐targeted effects by reducing the undesired activations of CRISPR/Cas‐PT in nontargeted organs (e.g., heart, liver, spleen, lung, and kidney). Here, F2 is linked to neoplasm.